Research Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Relative risk of Hepatitis Occurrence in patients with Different types of Hematological Malignancies


Affiliations
1 Biology Department, College of Science, University of Baghdad, Baghdad, Iraq
     

   Subscribe/Renew Journal


This study aimed to assess the incidence of chronic hepatitis virus infections, viral reactivation cases, viral load follows up and prognostic significance in different types of hematologic malignancies. We investigated of hepatitis B surface antigen (HBsAg) and IgM-hepatitis C (HCV) among 118 blood samples with different types of malignancies, and follow up the viral load in positive cases after chemotherapy course. Results showed 19 (16.1%) case of viral hepatitis infection belong to HBsAg and IgM-HCV different hematological malignancy. Of these, 15 (12.7%) of HBsAg and 4 (3.4%) of HCV IgM positive cases recorded. More than 50% of hepatitis viral reactivation reported in ALL and NHL patients after chemotherapy treatment. Approximately, the relative risk value (RR) 3.22 (95% Cl 0.78-13.22) of cohort viral hepatitis reactivation similar to odds ratio (OR) value 3.65 (95% Cl 0.81-16.41) for malignancy. Thus, a rising occurrence and reactivation of viral hepatitis along with increasing malignancy incidence than non-malignancy individuals. In this study, the results obtained revealed that the incidence of levels of hepatitis infection (HBsAg and HCV IgM) begins to increase significantly at ALL and NHL than other types of leukemia. Although the lowest prevalence of HCV IgM was seen in studying groups, the HCV IgM reported in four types of malignancy. We showed that the reactivation of hepatitis viral infection mostly in patients aged less than 30 years old accompanied by AML cases, and followed in some cases of ALL, while the reactivation of viral hepatitis in older patients with CLL occurred. However, the mean age of patient malignancy associated with viral hepatitis reactivation was 39.74 ± 4.42 with highly significant between cases. Significantly, the mean viral load decreased after a month of viral therapy (3.646×103IU/ml) compared with before and after three months 16.966×103IU/ml and 23.943×103IU/ml, respectively. Prophylactic antiviral therapy should be administered to viral hepatitis carriers before and during chemotherapy, and maintenance treatment for 6 months to reduce reactivation and exacerbation risk.

Keywords

Hepatitis Virus B and C, Hematological Malignancies, ELISA Assay, Viral Load, Real-Time PCR.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Katzel JA, Hari P and Vesole DH. Multiple myeloma: charging toward a bright future. CA Cancer J Clin. 57; 2007: 301-18.

  • Mark T, Niesvizky R and Coleman M. Novel agents in myeloma: an exciting saga. Cancer. 115; 2009: 236-42.

  • Kang J, Cho JH, Suh CW, Lee DH, Oh HB and Sohn YH. High prevalence of hepatitis B and hepatitis C virus infections in Korean patients with hematopoietic malignancies. Ann Hematol. 90(2); 2011: 159-64.

  • Shouval D and Shibolet O. Immunosuppression and HBV reactivation. Semin Liver Dis. 33; 2013: 167–177.

  • Engels EA. Infectious agents as causes of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 16 (3); 2007: 401-4.

  • Anderson LA, Pfeiffer R, Warren JL, Landgren O, Gadalla S and Berndt SI. Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev. 17(11); 2008: 3069-75.

  • Kiran M, Chawla YK and Kaur J. Methylation profiling of tumor suppressor genes and oncogenes in hepatitis virus-related hepatocellular carcinoma in northern India. Cancer Genet Cytogenet. 195(2); 2009: 112-9.

  • Oishi N, Shilagardi K, Nakamoto Y, Honda M, Kaneko S and Murakami S. Hepatitis B virus X protein overcomes oncogenic RAS-induced senescence in human immortalized cells. Cancer Sci.98(10); 2007: 1540-8.

  • Turner NC, Dusheiko G and Jones A. Hepatitis C and B-cell lymphoma. A review. Ann Oncol. 14; 2003: 1341-45.

  • Bianco E, Marcucci F and Mele A. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than Bcell non-Hodgkin’s lymphoma, and in myeloproliferative diseases: an Italian multicenter case-control study. Haematologica. 89; 2004: 70-76.

  • Peveling-Oberhag J, Arcaini L, Hansmann M and Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol. 59; 2013: 169–177.

  • Park SC, Jeong SH, Kim J, Han CJ, Kim YC and Choi KS. High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin’s lymphoma in Korea. J Med Virol. 80(6); 2008: 960-6.

  • Panfilio S, D'Urso P, Annechini G, D'Elia GM, De AngelisF, Stefanizzi C and Pulsoni A. Regression of a case of Multiple Myeloma with antiviral treatment in a patient with chronic HCV infection. Leukemia Research Reports 2; 2013: 39–40.

  • Chen CH, Yang PM, Huang GT, Lee HS, Sung JL and Sheu JC. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc. 106; 2007:148-55.

  • Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC and Lin SF. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatol. 47; 2008:844-53.

  • Lok ASF and McMohan BJ. AASLD practice guideline update. Chronic hepatitis B: update 2009. Hepatol. 50; 2009: 661-9.

  • Koo YX, Tan DS, Tan IB, Tao M, Chow WC and Lim ST. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer. 116; 2010:115-21.

  • Chen CY, Huang SY, Cheng A, Chou WC, Yao M, Tang JL, Tsay W, Sheng WH and Tien HF. High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia. PLoS One. 10(5); 2015: e0126037.

  • Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol. 17; 2011: 1531–1537.

  • Nakamura Y, Motokura T, Fujita A, Yamashita T and Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987–1991. Cancer. 78; 1996: 2210–2215.

  • Grossi S, Sumberaz A, Gosmar M, Mattioli F, Testino G and Martelli A. DNA damage in peripheral blood lymphocytes of patients with cirrhosis related to alcohol abuse or to hepatitis B and C viruses. Eur J Gastroenterol Hepatol. 20; 2008: 22-5.

  • Takai S, Tsurumi H and Ando K. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol. 74; 2005: 158-65.

  • Idilman R, Bozkus Y and Seval G. Lymphoproliferative disorders in individuals with chronic hepatitis B and C in Turkish population. J Med virol. 83(6); 2011: 974- 980.

  • Pham TNQ, Coffin CS and Michalak TI. Occult Hepatitis C virus infection; what does it mean?. Liver International. 30(4); 2010: 502-511.

  • Harrys A. Torres1 and George B. McDonald. How I treat hepatitis C virus infection in patients with hematologic malignancies. Blood J. 128(11); 2016: 1449-1457.

  • Tomizawa K, Suyama K, Matoba S, Hanaoka Y, Toda S, Moriyama J, Shimomura A, Miura Y, Kumada H and Kuroyanagi H. The safety of chemotherapy for colorectal cancer patients with hepatitis C virus infection. Med Oncol. 31; 2014:212-218.

  • Miura1Y, Theriault RL, Naito Y, Suyama K, Shimomura A, Iwatani T, Miura D, Kawabata H, Kumada H and Takano T. The Safety of Chemotherapy for Breast Cancer Patients with Hepatitis C Virus Infection. J Cancer. 4(6); 2013: 519-523.


Abstract Views: 291

PDF Views: 0




  • Relative risk of Hepatitis Occurrence in patients with Different types of Hematological Malignancies

Abstract Views: 291  |  PDF Views: 0

Authors

Hula Y. Fadhil
Biology Department, College of Science, University of Baghdad, Baghdad, Iraq

Abstract


This study aimed to assess the incidence of chronic hepatitis virus infections, viral reactivation cases, viral load follows up and prognostic significance in different types of hematologic malignancies. We investigated of hepatitis B surface antigen (HBsAg) and IgM-hepatitis C (HCV) among 118 blood samples with different types of malignancies, and follow up the viral load in positive cases after chemotherapy course. Results showed 19 (16.1%) case of viral hepatitis infection belong to HBsAg and IgM-HCV different hematological malignancy. Of these, 15 (12.7%) of HBsAg and 4 (3.4%) of HCV IgM positive cases recorded. More than 50% of hepatitis viral reactivation reported in ALL and NHL patients after chemotherapy treatment. Approximately, the relative risk value (RR) 3.22 (95% Cl 0.78-13.22) of cohort viral hepatitis reactivation similar to odds ratio (OR) value 3.65 (95% Cl 0.81-16.41) for malignancy. Thus, a rising occurrence and reactivation of viral hepatitis along with increasing malignancy incidence than non-malignancy individuals. In this study, the results obtained revealed that the incidence of levels of hepatitis infection (HBsAg and HCV IgM) begins to increase significantly at ALL and NHL than other types of leukemia. Although the lowest prevalence of HCV IgM was seen in studying groups, the HCV IgM reported in four types of malignancy. We showed that the reactivation of hepatitis viral infection mostly in patients aged less than 30 years old accompanied by AML cases, and followed in some cases of ALL, while the reactivation of viral hepatitis in older patients with CLL occurred. However, the mean age of patient malignancy associated with viral hepatitis reactivation was 39.74 ± 4.42 with highly significant between cases. Significantly, the mean viral load decreased after a month of viral therapy (3.646×103IU/ml) compared with before and after three months 16.966×103IU/ml and 23.943×103IU/ml, respectively. Prophylactic antiviral therapy should be administered to viral hepatitis carriers before and during chemotherapy, and maintenance treatment for 6 months to reduce reactivation and exacerbation risk.

Keywords


Hepatitis Virus B and C, Hematological Malignancies, ELISA Assay, Viral Load, Real-Time PCR.

References